Intersect ENT stock plunges 25% on disappointing earnings

Intersect ENT's stock plunged almost 25% after the maker of bioresorbable drug-eluting implants for conditions of the ear, nose and throat reported a loss of $9.7 million on sales of $14.2 million. The financials were below expectations; the loss increased 65.5% year over year. More on its earnings